Abstract
The purpose of the paper is to summarize recommendations that are broadly applicable, provide an up-to-date summary of the evidence available, and provide information to healthcare professionals regarding the use of medications in the context of moderate-to-severe pulmonary infections. SARS-CovV2 disease. It would be advisable for all therapeutic interventions outside of official recommendations and without prior evidence to be included in research protocols.
Keywords
Pneumonia; Pharmacological treatment; Adult patients; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Tractament de la pneumònia per SARS-CoV-2. Barcelona: Servei Català de la Salut; 2020.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/9873.2This item appears in following collections
The following license files are associated with this item: